Skip to main content

02-07-2019 | Multiple sclerosis | Video

EAN 2019: Ozanimod protects against brain volume loss in relapsing MS

Giancarlo Comi comments on the SUNBEAM and RADIANCE trial findings looking at the effects of ozanimod versus interferon beta-1α on brain volume loss in relapsing multiple sclerosis (1:50).

Funding for independent interviews at EAN 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits